GI-101A
Phase 2Immuno-oncology candidate in a randomized phase 2 combination study with a checkpoint inhibitor.
FROM PUBLIC EVENTS · 2026-11-15
Early clinical · first deals Testing several immuno-oncology candidates in trials at home and abroad while generating new ones.
Roles often seen at this stageClinical & PV · Research & development · BD & licensing
A biotech developing bispecific fusion proteins for immuno-oncology, testing several candidates in clinical trials in Korea and abroad.
Immuno-oncology candidate in a randomized phase 2 combination study with a checkpoint inhibitor.
Immuno-oncology candidate whose subcutaneous phase 1 dose-escalation results were presented at a congress.
Protein-design platform for generating new candidates.
Presented two new platform-derived candidates as posters at the AACR annual meeting.
Received approval for an amended phase 1/2 trial plan.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.